Produktname:5-isothiocyanato-3-(trifluoromethyl)pyridine-2-carbonitrile
IUPAC Name:5-isothiocyanato-3-(trifluoromethyl)pyridine-2-carbonitrile
- CAS：951753-87-0
- Molekulare Formel：C8H2F3N3S
- Reinheit：98%
- Katalognummer：CM327941
- Molekulargewicht：229.18
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:951753-87-0
- Molekulare Formel:C8H2F3N3S
- Schmelzpunkt:-
- SMILES-Code:N#CC1=NC=C(N=C=S)C=C1C(F)(F)F
- Dichte:
- Katalognummer:CM327941
- Molekulargewicht:229.18
- Siedepunkt:
- Mdl-Nr.:
- Lagerung:
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- Apalutamide
- Johnson & Johnson announced results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP). Following RP, patients who received the treatment regimen showed a 100% biochemical recurrence (BCR)–free rate at 24 months. ERLEADA® (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Suche 
+86 21 5895 0110 
